Clinical Trials Logo

Rectal Neoplasms clinical trials

View clinical trials related to Rectal Neoplasms.

Filter by:
  • Enrolling by invitation  
  • « Prev · Page 2

NCT ID: NCT02751736 Enrolling by invitation - Rectal Cancer Clinical Trials

The Effect Of Probiotics On Bowel Function Restoration After Ileostomy Closure In Patients With Rectal Cancer

Start date: April 2016
Phase: N/A
Study type: Interventional

The study will investigate whether Probiotics(CJLP243) given just before and after ileostomy repair operation in patient with rectal cancer improve a bowel function.

NCT ID: NCT02488707 Enrolling by invitation - Rectal Cancer Clinical Trials

Minimally Invasive Sphincter Sparing Total Mesorectal Excision for Ultra-low Rectal Cancer After Initial Chemo-radiotherapy (MISS-TRICR).

MISS-TRICR
Start date: February 2014
Phase: Phase 2
Study type: Interventional

A prospective study is planned for management of low rectal cancer with the aim of sphincter preservation and improving the oncological outcome of the patients, through comparing of both approaches minimally invasive techniques including transanal total mesorectal excision and laparoscopic intersphincteric resection.

NCT ID: NCT02488577 Enrolling by invitation - Low Rectal Cancer Clinical Trials

Outcomes of TAMIS-Total Mesorectal Excision Versus Transanal Loco-regional Excision for T2 Low Rectal Cancer

TAMIS
Start date: June 2015
Phase: N/A
Study type: Interventional

Cases with stage T2 N0 low rectal cancer will undergo either Transanal minimally invasive total mesorectal excision or transanal minimally invasive locoregional resection.

NCT ID: NCT02468362 Enrolling by invitation - Low Rectal Cancer Clinical Trials

Long Term Outcomes After Laparoscopic Intersphincteric Resection With Total Mesorectal Excision for Low Rectal Cancer.

ISR-TME
Start date: April 2014
Phase: Phase 2
Study type: Interventional

Through a double blinded study, patients with low rectal cancer will be randomized into two equal groups to compare between the 5 year disease free survival as a primary outcome measure.